CancerFLACC-BrazilNCT06965608
Feasibility Study to Actively Disseminate the Latin America and the Caribbean Code Against Cancer in Primary Healthcare Centers
A study testing WhatsApp-Based Cancer Prevention Messaging, Online Cancer Prevention Workshop for Healthcare Professionals and Combined WhatsApp Messaging and Online Workshop in people with Cancer and Latin America and the Caribbean Code Against Cancer (LAC Code), run by Hospital Israelita Albert Einstein at 1 site in Brazil.
Trial summary
Phase II non-randomized four-arm study (before/after pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer, Latin America and the Caribbean Code Against Cancer (LAC Code)
- What is being tested?
- WhatsApp-Based Cancer Prevention Messaging, Online Cancer Prevention Workshop for Healthcare Professionals and Combined WhatsApp Messaging and Online Workshop
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 1 siteBrazil
- Study dates
- May 2025to Nov 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults (≥18 years old)
- Registered at a participating primary healthcare center (UBS) in Aparecida de Goiânia
- Healthcare professionals with at least three months of employment at a participating UBS
- Ability to provide informed consent
Who cannot join
- Prior diagnosis of any cancer or currently undergoing cancer treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site
HMAP - Hospital Municipal de Aparecida de Goiânia
Aparecida de Goiânia, Goiás
Mayler O. N. de Santos, MD, +55 62 3878-5100, mayler.santos@einstein.br
About this study
Official title: Feasibility Study to Actively Disseminate the Latin America and the Caribbean Code Against Cancer in Primary Healthcare Centers in Aparecida de Goiania (Brazil) - FLACC-Brazil
Phase II non-randomized four-arm study (before/after pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia.
- Being tested
- WhatsApp-Based Cancer Prevention Messaging, Online Cancer Prevention Workshop for Healthcare Professionals, Combined WhatsApp Messaging and Online Workshop
- Keywords
- Health Literacy, Cancer Prevention, Health Services Research, Implementation Science, Latin America and the Caribbean Code Against Cancer (LAC Code)
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WhatsApp-Based Cancer Prevention MessagingBehavioural
Participants in this group will receive a structured series of WhatsApp messages containing evidence-based cancer prevention recommendations from the Latin America and Caribbean Code Against Cancer (LAC Code). Messages will be delivered over four weeks, 3 times a week, covering key topics such as smoking cessation, healthy diet, physical activity, and regular screening. Engagement metrics will be tracked to assess feasibility and adherence.
Online Cancer Prevention Workshop for Healthcare ProfessionalsBehavioural
Healthcare professionals assigned to this group will participate in an online workshop designed to improve their knowledge of the LAC Code and communication strategies for cancer prevention counseling. The workshop includes recorded lectures, interactive modules, and knowledge assessments. Completion rates and participant satisfaction will be measured.
Combined WhatsApp Messaging and Online WorkshopBehavioural
Participants in this group will receive both interventions: WhatsApp messages with cancer prevention recommendations and access to the online workshop. The intervention aims to assess whether a combined approach enhances adherence and impact. Engagement with both interventions will be monitored.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | No intervention | Participants in this arm will receive no intervention during the study period. They will complete baseline and follow-up assessments to evaluate changes in cancer prevention literacy and health services-related outcomes over time, serving as a comparison for the intervention arms. |
| G1: WhatsApp Messaging Intervention - General Population | Experimental | Participants in this arm will receive structured cancer prevention messages via WhatsApp over a four-week period. The messages will cover key recommendations from the Latin America and the Caribbean Code Against Cancer (LAC Code), focusing on actionable steps to reduce cancer risk. Healthcare professionals (HCPs) assigned to this group will not receive any training. Receives: Behavioral: WhatsApp-Based Cancer Prevention Messaging |
| G2: Online Workshop for Healthcare Professionals (HCP) | Experimental | Description: Healthcare professionals (HCPs) in this arm will participate in an online, self-paced workshop designed to enhance their knowledge and communication skills related to cancer prevention. The workshop will provide evidence-based training on discussing cancer risk factors and prevention strategies with patients, aligning with the LAC Code recommendations. General population participants assigned to this group will not receive WhatsApp messages. Receives: Behavioral: Online Cancer Prevention Workshop for Healthcare Professionals |
| G3: Combined Intervention (WhatsApp + Workshop) | Experimental | This arm will integrate both intervention strategies. General population participants will receive WhatsApp messages with cancer prevention recommendations, while healthcare professionals will complete the online workshop. This combined approach aims to assess whether reinforcing cancer prevention messages at both the community and healthcare provider levels leads to improved outcomes in cancer prevention literacy and health services utilization. Receives: Behavioral: Combined WhatsApp Messaging and Online Workshop |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of the WhatsApp-Based Intervention
Number of participants who report having read at least one WhatsApp message.
Measured: Up to 2 weeks after WhatsApp intervention completion
Acceptability of the WhatsApp-Based Intervention
Mean acceptability score from participant survey (Likert scale 1-5) evaluating message usefulness and clarity.
Measured: Up to 2 weeks after WhatsApp intervention completion
Appropriateness of the WhatsApp-Based Intervention
Proportion of participants who indicate willingness to receive similar messages in the future (Yes/No).
Measured: Up to 2 weeks after WhatsApp intervention completion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study startMay 2025 (estimated)
- Primary completionOct 2025 (estimated)
- Study completionNov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Non-randomized four-arm study (before/after pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia.
- Masking
- None (open label)
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Israelita Albert Einstein
- Sponsor type
- University, hospital or other
- Collaborators
- International Agency for Research on Cancer
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06965608
- Sponsor's protocol ID
- LACCODE - FLACC-Brazil
- Acronym
- FLACC-Brazil
- Status last verified
- Apr 2025
- First submitted
- 20 Mar 2025
- Last updated
- 11 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to privacy considerations and institutional policies governing data access. However, aggregated and de-identified study results will be shared through peer-reviewed publications and conference presentations.
Publications
Busetto L, Wick W, Gumbinger C. How to use and assess qualitative research methods. Neurol Res Pract. 2020 May 27;2:14. doi: 10.1186/s42466-020-00059-z. eCollection 2020.
PubMed 33324920Espina C, Feliu A, Gonzalez Vingut A, Liddle T, Jimenez-Garcia C, Olaya-Caro I, Perula-De-Torres LA. Population-Based Cancer Prevention Education Intervention Through mHealth: A Randomized Controlled Trial. J Med Syst. 2024 Jan 9;48(1):9. doi: 10.1007/s10916-023-02026-y.
PubMed 38194118Delucchi KL, Tajima B, Guydish J. Development of the Smoking Knowledge, Attitudes, and Practices (S-KAP) Instrument. J Drug Issues. 2009 Mar;39(2):347-364. doi: 10.1177/002204260903900207.
PubMed 20717496Nardi A, Mitrova S, Angelici L, De Gregorio CG, Biliotti D, De Vito C, Vecchi S, Davoli M, Agabiti N, Acampora A. Developing a Questionnaire Evaluating Knowledge, Attitudes and Behaviors on Audit & Feedback among General Practitioners: A Mixed Methods Study. Healthcare (Basel). 2023 Apr 24;11(9):1211. doi: 10.3390/healthcare11091211.
PubMed 37174753Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217-24. doi: 10.31887/DCNS.2011.13.2/npatsopoulos.
PubMed 21842619Espina C, Feliu A, Maza M, Almonte M, Ferreccio C, Finck C, Herrero R, Dommarco JR, de Almeida LM, Arrossi S, Garcia PJ, Garmendia ML, Mohar A, Murillo R, Santamaria J, Tortolero-Luna G, Cazap E, Gabriel OO, Paonessa D, Zoss JW, Luciani S, Carvalho A, Schuz J; Working Groups of Scientific Experts. Latin America and the Caribbean Code Against Cancer 1st Edition: 17 cancer prevention recommendations to the public and to policy-makers (World Code Against Cancer Framework). Cancer Epidemiol. 2023 Oct;86 Suppl 1:102402. doi: 10.1016/j.canep.2023.102402. Epub 2023 Oct 16.
PubMed 37852725Fleary SA, Paasche-Orlow MK, Joseph P, Freund KM. The Relationship Between Health Literacy, Cancer Prevention Beliefs, and Cancer Prevention Behaviors. J Cancer Educ. 2019 Oct;34(5):958-965. doi: 10.1007/s13187-018-1400-2.
PubMed 30022378Morris NS, Field TS, Wagner JL, Cutrona SL, Roblin DW, Gaglio B, Williams AE, Han PJ, Costanza ME, Mazor KM. The association between health literacy and cancer-related attitudes, behaviors, and knowledge. J Health Commun. 2013;18 Suppl 1(Suppl 1):223-41. doi: 10.1080/10810730.2013.825667.
PubMed 24093358Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldana K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015 Oct;16(14):1405-38. doi: 10.1016/S1470-2045(15)00218-1.
PubMed 26522157Barrios CH, Werutsky G, Mohar A, Ferrigno AS, Muller BG, Bychkovsky BL, Castro E CJ, Uribe CJ, Villarreal-Garza C, Soto-Perez-de-Celis E, Gutierrez-Delgado F, Kim JS, Ismael J, Delgado L, Santini LA, Teich N, Chavez PC, Liedke PER, Exman P, Barroso-Sousa R, Stefani SD, Caceres SAB, Rebelatto TF, Pastrana T, Chavarri-Guerra Y, Vargas Y, Cazap E. Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncol. 2021 Nov;22(11):e474-e487. doi: 10.1016/S1470-2045(21)00492-7.
PubMed 34735817Rezende LFM, Lee DH, Louzada MLDC, Song M, Giovannucci E, Eluf-Neto J. Proportion of cancer cases and deaths attributable to lifestyle risk factors in Brazil. Cancer Epidemiol. 2019 Apr;59:148-157. doi: 10.1016/j.canep.2019.01.021. Epub 2019 Feb 14.
PubMed 30772701
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study to Actively Disseminate the Latin America and the Caribbean Code Against Cancer in Primary Healthcare Centers in Aparecida de Goiania (Brazil) - FLACC-Brazil
- ClinicalTrials.gov ID
- NCT06965608
- Acronym / sponsor ID
- FLACC-Brazil / LACCODE - FLACC-Brazil
- Keywords
- Health Literacy, Cancer Prevention, Health Services Research, Implementation Science, Latin America and the Caribbean Code Against Cancer (LAC Code)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Hospital Israelita Albert EinsteinUniversity, hospital or other
- Collaborators
- International Agency for Research on Cancer
- Study start
- May 2025 (estimated)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Nov 2025 (estimated)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Phase II non-randomized four-arm study (before/after pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Non-randomized four-arm study (before/after pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia.
| Arm | Type | Receives |
|---|---|---|
| Control Group | No intervention | –Participants in this arm will receive no intervention during the study period. They will complete baseline and follow-up assessments to evaluate changes in cancer prevention literacy and health services-related outcomes over time, serving as a comparison for the intervention arms. |
| G1: WhatsApp Messaging Intervention - General Population | Experimental | Behavioral: WhatsApp-Based Cancer Prevention MessagingParticipants in this arm will receive structured cancer prevention messages via WhatsApp over a four-week period. The messages will cover key recommendations from the Latin America and the Caribbean Code Against Cancer (LAC Code), focusing on actionable steps to reduce cancer risk. Healthcare professionals (HCPs) assigned to this group will not receive any training. |
| G2: Online Workshop for Healthcare Professionals (HCP) | Experimental | Behavioral: Online Cancer Prevention Workshop for Healthcare ProfessionalsDescription: Healthcare professionals (HCPs) in this arm will participate in an online, self-paced workshop designed to enhance their knowledge and communication skills related to cancer prevention. The workshop will provide evidence-based training on discussing cancer risk factors and prevention strategies with patients, aligning with the LAC Code recommendations. General population participants assigned to this group will not receive WhatsApp messages. |
| G3: Combined Intervention (WhatsApp + Workshop) | Experimental | Behavioral: Combined WhatsApp Messaging and Online WorkshopThis arm will integrate both intervention strategies. General population participants will receive WhatsApp messages with cancer prevention recommendations, while healthcare professionals will complete the online workshop. This combined approach aims to assess whether reinforcing cancer prevention messages at both the community and healthcare provider levels leads to improved outcomes in cancer prevention literacy and health services utilization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults (≥18 years old)
- Registered at a participating primary healthcare center (UBS) in Aparecida de Goiânia
- Healthcare professionals with at least three months of employment at a participating UBS
- Ability to provide informed consent
Key exclusion criteria (1 listed)
- Prior diagnosis of any cancer or currently undergoing cancer treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WhatsApp-Based Cancer Prevention MessagingParticipants in this group will receive a structured series of WhatsApp messages containing evidence-based cancer prevention recommendations from the Latin America and Caribbean Code Against Cancer (LAC Code). Messages will be delivered over four weeks, 3 times a week, covering key topics such as smoking cessation, healthy diet, physical activity, and regular screening. Engagement metrics will be tracked to assess feasibility and adherence. | Behavioural | G1: WhatsApp Messaging Intervention - General Population |
| Online Cancer Prevention Workshop for Healthcare ProfessionalsHealthcare professionals assigned to this group will participate in an online workshop designed to improve their knowledge of the LAC Code and communication strategies for cancer prevention counseling. The workshop includes recorded lectures, interactive modules, and knowledge assessments. Completion rates and participant satisfaction will be measured. | Behavioural | G2: Online Workshop for Healthcare Professionals (HCP) |
| Combined WhatsApp Messaging and Online WorkshopParticipants in this group will receive both interventions: WhatsApp messages with cancer prevention recommendations and access to the online workshop. The intervention aims to assess whether a combined approach enhances adherence and impact. Engagement with both interventions will be monitored. | Behavioural | G3: Combined Intervention (WhatsApp + Workshop) |
Primary outcome
Feasibility of the WhatsApp-Based Intervention
Time frame: Up to 2 weeks after WhatsApp intervention completion
Number of participants who report having read at least one WhatsApp message.
Acceptability of the WhatsApp-Based Intervention
Time frame: Up to 2 weeks after WhatsApp intervention completion
Mean acceptability score from participant survey (Likert scale 1-5) evaluating message usefulness and clarity.
Appropriateness of the WhatsApp-Based Intervention
Time frame: Up to 2 weeks after WhatsApp intervention completion
Proportion of participants who indicate willingness to receive similar messages in the future (Yes/No).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2025.
- Background: PubMed 33324920Busetto L, Wick W, Gumbinger C. How to use and assess qualitative research methods. Neurol Res Pract. 2020 May 27;2:14. doi: 10.1186/s42466-020-00059-z. eCollection 2020.
- Background: PubMed 38194118Espina C, Feliu A, Gonzalez Vingut A, Liddle T, Jimenez-Garcia C, Olaya-Caro I, Perula-De-Torres LA. Population-Based Cancer Prevention Education Intervention Through mHealth: A Randomized Controlled Trial. J Med Syst. 2024 Jan 9;48(1):9. doi: 10.1007/s10916-023-02026-y.
- Background: PubMed 20717496Delucchi KL, Tajima B, Guydish J. Development of the Smoking Knowledge, Attitudes, and Practices (S-KAP) Instrument. J Drug Issues. 2009 Mar;39(2):347-364. doi: 10.1177/002204260903900207.
- Background: PubMed 37174753Nardi A, Mitrova S, Angelici L, De Gregorio CG, Biliotti D, De Vito C, Vecchi S, Davoli M, Agabiti N, Acampora A. Developing a Questionnaire Evaluating Knowledge, Attitudes and Behaviors on Audit & Feedback among General Practitioners: A Mixed Methods Study. Healthcare (Basel). 2023 Apr 24;11(9):1211. doi: 10.3390/healthcare11091211.
- Background: PubMed 21842619Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217-24. doi: 10.31887/DCNS.2011.13.2/npatsopoulos.
- Background: PubMed 37852725Espina C, Feliu A, Maza M, Almonte M, Ferreccio C, Finck C, Herrero R, Dommarco JR, de Almeida LM, Arrossi S, Garcia PJ, Garmendia ML, Mohar A, Murillo R, Santamaria J, Tortolero-Luna G, Cazap E, Gabriel OO, Paonessa D, Zoss JW, Luciani S, Carvalho A, Schuz J; Working Groups of Scientific Experts. Latin America and the Caribbean Code Against Cancer 1st Edition: 17 cancer prevention recommendations to the public and to policy-makers (World Code Against Cancer Framework). Cancer Epidemiol. 2023 Oct;86 Suppl 1:102402. doi: 10.1016/j.canep.2023.102402. Epub 2023 Oct 16.
- Background: PubMed 30022378Fleary SA, Paasche-Orlow MK, Joseph P, Freund KM. The Relationship Between Health Literacy, Cancer Prevention Beliefs, and Cancer Prevention Behaviors. J Cancer Educ. 2019 Oct;34(5):958-965. doi: 10.1007/s13187-018-1400-2.
- Background: PubMed 24093358Morris NS, Field TS, Wagner JL, Cutrona SL, Roblin DW, Gaglio B, Williams AE, Han PJ, Costanza ME, Mazor KM. The association between health literacy and cancer-related attitudes, behaviors, and knowledge. J Health Commun. 2013;18 Suppl 1(Suppl 1):223-41. doi: 10.1080/10810730.2013.825667.
- Background: PubMed 26522157Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldana K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015 Oct;16(14):1405-38. doi: 10.1016/S1470-2045(15)00218-1.
- Background: PubMed 34735817Barrios CH, Werutsky G, Mohar A, Ferrigno AS, Muller BG, Bychkovsky BL, Castro E CJ, Uribe CJ, Villarreal-Garza C, Soto-Perez-de-Celis E, Gutierrez-Delgado F, Kim JS, Ismael J, Delgado L, Santini LA, Teich N, Chavez PC, Liedke PER, Exman P, Barroso-Sousa R, Stefani SD, Caceres SAB, Rebelatto TF, Pastrana T, Chavarri-Guerra Y, Vargas Y, Cazap E. Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncol. 2021 Nov;22(11):e474-e487. doi: 10.1016/S1470-2045(21)00492-7.
- Background: PubMed 30772701Rezende LFM, Lee DH, Louzada MLDC, Song M, Giovannucci E, Eluf-Neto J. Proportion of cancer cases and deaths attributable to lifestyle risk factors in Brazil. Cancer Epidemiol. 2019 Apr;59:148-157. doi: 10.1016/j.canep.2019.01.021. Epub 2019 Feb 14.
- GLOBOCANLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to privacy considerations and institutional policies governing data access. However, aggregated and de-identified study results will be shared through peer-reviewed publications and conference presentations.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WhatsApp-Based Cancer Prevention Messaging, Online Cancer Prevention Workshop for Healthcare Professionals and Combined WhatsApp Messaging and Online Workshop in people with Cancer and Latin America and the Caribbean Code Against Cancer (LAC Code), run by Hospital Israelita Albert Einstein at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Diogo G Bugano, MD (+551121511233, diogo.gomes@einstein.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of the WhatsApp-Based Intervention (time frame: Up to 2 weeks after WhatsApp intervention completion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06965608, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2025.